ProCE Banner Activity

Individualizing Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer in Your Practice

Slideset

Download this slideset on the management of patients with metastatic HR-positive/HER2-negative breast cancer including the current treatment algorithm, recommended biomarker testing, and the management of key adverse events associated with oral therapies.

Released: April 01, 2025

Expiration: March 31, 2026

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly